While CD26/DPP4 seems to be an interesting possible novel therapeutic target when topically inhibited, undesirable effects have to be apprehended and the continuous use of oral DPP4 inhibitors should be carefully monitored in comorbid patients suffering from diabetes mellitus type 2 as well as from asthma or other allergic diseases. Here, DPP4 is linked to allergic disease.